VC/PE/M&A. Healthcare Weekly(2017.12.05)

 2017-12-05 A- A+




Codiak BioSciences融资7700万美元,外泌体治疗理念挑战学界权威。

飞利浦收购Analytical Informatics,医学影像领域也要完善工作流!


私募融资 & IPO


概要:近期,位于比利时布鲁塞尔的液体活检公司Biocartis融资8000万欧元,用于扩展产品线,并且发展销售和产能。Biocartis目前主要研发Idylla聚合酶链式反应(Polymerase chain reaction,简称PCR)自动化诊断系统,这一系统自2014年首发,用于检测肿瘤和传染病相关的临床结果,目前正在进入美国市场。该公司还计划明年研发一款使用EGFR变异液体检测方法来检测肺癌的液体活检仪。



Biocartis raises €80M to help drive liquid biopsy push

Nov 29, 2017

Belgian molecular diagnostics outfit Biocartis says an €80 million private placement will allow it to expand its product range and sales and manufacturing capacity. The Brussels-listed company had originally hoped to raise around €60 million, but topped that target by placing 6.4 million new shares at an issue price of €12.50 a piece that, according to chief financial officer Ewoud Welten, “is an important milestone for Biocartis in securing funds for the further execution of its plans.” The cash injection will go towards expanding the range of tests offered with Biocartis’ Idylla automated polymerase chain reaction (PCR) diagnostics system—first launched in 2014 and just starting to roll out in the U.S.—that is used to test clinical samples, mainly in oncology, infectious diseases. It will also go towards bulking up its sales and marketing teams and adding production capacity for Idylla’s diagnostic test capsules, said Welten.

Just this week, the company launched two new liquid biopsy tests for the detection of RAS mutations in patients with metastatic colorectal cancer, a project it has partnered with German drug and chemicals groups Merck KGaA. Merck’s second-biggest product Erbitux (cetuximab) is used to treat colorectal cancer, and RAS testing is a key toll in deciding which patients stand to benefit from treatment with the drug. The company sees the development of liquid biopsy tests as a key part of its growth strategy, allowing it to broaden access to molecular diagnostics by allowing analysis to be carried out on blood samples rather than surgical biopsies. “Liquid biopsy testing is at the advanced edge of oncology practice, where it has the ability to complement tissue testing and provide additional prognostic information that was not available to clinicians so far,” commented Biocartis’ head of R&D Erwin Sablon. Earlier this year the Mechelen-based firm formed a partnership with U.K. medical research charity MRC Technology to develop a liquid biopsy test that will be used to monitor metastatic breast cancer patients for resistance to hormone therapy. Biocartis followed that with a separate deal to develop an Idylla-compatible version of Genomic Health’s Oncotype DX Breast Recurrence Score test, which predicts whether patients will benefit from chemotherapy. Next year, the platform should be extended further with the launch of a liquid biopsy test for EGFR mutations in lung cancer patients. Biocartis already has a solid biopsy version of the test available on Idylla which picked up a CE Mark in June.

Source: FierceBiotech

2.Codiak BioSciences融资7700万美元,外泌体治疗理念挑战学界权威

概要:专注外泌体治疗的美国麻省生物科技公司CodiakBioSciences成功实现C轮融资7650万美元,公司瞬间升值到1.7亿美元,为其外来体治疗候选药物的临床试验铺平了道路。Codiak于2015年成立,领导团队成员为Biogen的前任研发主管Doug Williams,当时获得的风投数额未3100万美元。仅数个月之后,Codiak就完成了由Arch VenturePartners,Flagship Ventures和其他投资者参与的B轮融资。此轮投资中,Arch和Flagship等投资方都继续为公司注资。尽管自A轮融资之后,Codiak的发展规划就有所变更,但其对于外来体治疗的专注从未改变。该公司得以安身立命的研发基础就是对于外来体超出一般的清除细胞垃圾的功能的认知。这一理念一开始并不为外界所广泛接受,但是相信经过后续的临床试验,Codiak将会扫除观念上的障碍。


Codiak CEO Doug Williams


Codiak raises $77M to trial exosome-enabled therapies

Nov 29, 2017

Codiak BioSciences has raised $76.5 million.The series C, which moves Codiak’s total haul up toward $170 million, tees theexosome-focused biotech up to move its lead candidate into clinical trials. Cambridge, Massachusetts-based Codiak emergedin 2015 boasting a leadership team headed by ex-Biogen R&D chief Doug Williams and $31 million in venture funding. A $61 million series B followed just months later as Arch Venture Partners, Flagship Ventures and other investors comfortable placing big bets on biotech piled in. Arch, Flagship and other existing investors have returned for the $76.5 million round, which marks the point Codiak sets its sights on the clinic. At the time of the series A, Williams talked up the possibility of getting into phase 1 in 2016. But Codiak is now at the point ithas initial product candidates ready to push through the final steps in thepreclinical process. While the timelines have shifted somewhatsince the series A, Codiak’s scientific focus has held steady. The biotech wasfounded on the back of research that expanded understanding of the role ofexosomes beyond cellular trash removal. That led to recognition it may be possible tohustle nucleic acids and other macromolecules into cells hidden inside exosomes, thereby bypassing the mechanism the body uses to repel invaders. In June, an MD Anderson team including RaghuKalluri, M.D., Ph.D., who was an early collaborator with Codiak, showed uptakeof RNAi-laden exosomes by pancreatic tumors in mice. That raised hopes theapproach can drug KRAS, a hard-to-hit location of oncogenic mutations. But itleft the question of whether the payload suffers lysosome-dependent degradationunanswered. Codiak is now nearly ready to start dispellingdoubts with clinical data. “Investors are clearly seeing the versatility of exosomes as a therapeutic platform with broad utility and the capacity toaddress currently undruggable targets, offering multiple paths to clinical andcommercial success,” Williams said in a statement. Codiak has succeeded in selling the potentialof the idea to a clutch of new investors, including Qatar Investment Authority. The $300 billion-plus sovereign wealth fund has participated in majorinvestments in emerging tech giants Flipkart and Uber, plus car maker Karma Automotive, over the past decade. But in general is better known for itsinvestments in real estate than startups. The fund’s participation in the Codiak roundis one indication that could be about to change. QIA is planning to open anoffice in San Francisco to add to its existing presence in New York,potentially positioning it to get deeper into tech and biotech startups. And,despite the difficulties created by the blockade of the country, the CEO of thefund has talked up plans to invest big, not back out.

Source: FierceBiotech


1. 飞利浦收购Analytical Informatics,医学影像领域也要完善工作流!

概要:飞利浦上周宣布收购影像学工作流解决方案提供者Analytical Informatics,具体交易金额未透露。通过这一收购,飞利浦力图充实其PerformanceBridge组合(飞利浦旗下的运营绩效改善软件和服务系统)。Analytical Informatics于2011年从马里兰大学拆分出来,成为了一家独立的公司。它基于马里兰大学医学院的专利,致力于完善与厂商无关的工作流领域的解决工具和应用。飞利浦表示,Analytical Informatics能够通过技术、分析和现场专业服务,在很大程度上为医学影像服务者提供操作上的便利。


Philips snaps up imaging workflow provider Analytical Informatics

Nov 27, 2017

Royal Philips (NYSE:PHG) said last week that it spent an unspecified sum to acquire imaging workflow solutions provider Analytical Informatics to beef up its Performance Bridge portfolio. Founded in 2011 and spun out of the University of Maryland, Baltimore-based Analytical Informationatics offers vendor-agnostic workflow tools and applications based on technology licensed from the university’s medical school, Philips said. “Integrating Analytical Informatics’ software tools and applications into our current offerings will enable us to accelerate the delivery of next-generation technology, software and services, to bring the power of operational intelligence and decision support to radiology,” radiology solutions GM Sham Sokka said in prepared remarks. “We’ll be in an even stronger position to provide our customers with a host of solutions and help them maximize opportunities to do more with less, while delivering patient-centric care.” The Dutch healthcare conglomerate said Performance Bridge is designed to improve operational performance for imaging providers using technology, analytics and on-site and professional services. The Performance Bridge Practice component, into which the company plans to integrate the Analytical Informatics tech, aims to “help imaging departments simplify and unify various levels of data and unlock actionable information,” Philips said. The company also said it plans to add the ability to gauge utilization and volume rates across several imaging modalities to PerformanceBridge, plus a feature that would “identify opportunities for MR imaging protocol optimization, standardization and efficiency improvements.”

Source: MassDevice


概要:位于英国伦敦的医疗公司LivaNova近期宣布将于2018年第二季度正式将其旗下的Cardiac Rhythm Management(心律管理,以下简称CRM)业务卖给其合资人MicroPort Scientific。LivaNova的CRM业务专攻心力衰竭和心律不齐等病症的诊疗器械(如除颤器、起搏器、心脏再同步治疗器械等)的研发和销售。公司自2014年就和MicroPort Scientific在中国成立了合资公司,其中Rega起搏器在中国获批,成为中国市场上型号最小的起搏器之一。CRM在欧洲和日本市场的成绩也非常显著,在2016财年为公司创下了2.49亿美元的净销售额。但由于LivaNova高层认为CRM业务不再适应公司发展的新方向,公司自去年9月起就在寻找其CRM的买主。


LivaNova to offload Cardiac Rhythm unit for$190M

Nov 20, 2017

LivaNova has inked a pactto sell its Cardiac Rhythm Management (CRM) business to its joint venture partner, MicroPort Scientific. The all-cash deal is slated to close in the second quarter of 2018. The London-based company has been seeking a buyer for its CRM unit since at least September. The business develops and markets devices for the diagnosis and treatment of heart failure and cardiac arrhythmias. These include defibrillators, pacemakers and cardiac resynchronization therapy devices.

Cardiac Surgery and Neuromodulation make up LivaNova’s two other businesses. CRM has a strong presence in Europe and Japan, posting $249 million in net sales for fiscal2016. But LivaNova is letting the business go, as it no longer fits in with the direction the company is going. “The CRM business franchise is a global business and strong regional player with attractive assets, a robust pipeline and growth potential,” said LivaNova CEO DamienMcDonald when the company announced its plans for the CRM business. “However,it is no longer a strategic fit within LivaNova’s portfolio.” LivaNova teamed up with MicroPort on a joint venture in 2014, to market its CRM devices in China. Theduo has made steady progress since then, notching a China FDA approval forLivaNova’s Rega pacemaker, which became one of the smallest pacemakers available in China. “With this divestiture,we are building the right foundation,” McDonald said in a statement. “We are focusing our portfolio on businesses that contribute to our growth and drive shareholder value. In addition to the implementation of other initiatives,completion of this milestone will allow LivaNova to improve margins, drive profitability and deliver on our commitments to shareholders.”

Source: FierceBiotech


1. 超过660亿美元收购计划敲定本周重磅!CVS将收购Aetna,剑指美国诊所市场



CVS eyes major expansion of health clinics with Aetna deal – sources

Dec 1, 2017

NEW YORK (Reuters) - CVS Health Corp (CVS.N) is planning to significantly expand health services at its retail pharmacies if it completes a more than $66 billion deal for insurer Aetna Inc (AET.N), a move that could save more than $1 billion annually, people familiar with the matter said. A key rationale is to use many of the U.S. pharmacy chain’s 9,700 brick-and-mortar outlets to improve access to preventative care and cut back on some emergency room visits for Aetna’s roughly 23 million members with medical coverage, these people said. The full benefits of the strategy will take several years to realize, requiring billions of dollars in investment to increase the number of CVS clinics and provide the staff and equipment for a wider variety of treatments, the people said. Those funds would be diverted from planned investments in CVS retail facilities, and not amount to additional expenses, they said.

Deal talks between the companies are still underway, and an agreement could be announced as early as Sunday or Monday, sources familiar with the matter told Reuters. It is also possible that a deal is delayed or does not materialize, they said. Health insurers have redoubled their efforts to cut costs in a time of steep prescription drug price rises and requirements to care for even the sickest patients under the Affordable Care Act. Aetna last year tried to buy rival Humana Inc (HUM.N) to gain more leverage over costs, but that transaction, as well as a proposed merger between Anthem Inc (ANTM.N) and Cigna Corp (CI.N), was shot down by antitrust regulators. Many insurers have already been encouraging patients to use urgent care centers, which can provide some of the same services as emergency rooms for as little as a tenth of the cost, said Laurel Stoimenoff, chief executive of the Urgent Care Association of America.

Source: Reuters

肖恩大侠 华盖医疗基金董事总经理,北京。 毕业于北京大学工学院医学院(医学硕士)、北京大学法学院(法学硕士)。资浅PE从业人士。躬耕于太湖,游学至未名,当过医生,学过法律,改行至风险投资,喜好读书写作,经史文集,现代科技都甚喜欢,总是怀着理想,万一,实现了呢?欢迎交流医疗、文化、消费,欢迎交流一级市场、二级市场,欢迎交流国内及海外并购。 邮箱